Concurrent Targeting of KRAS and AKT by MiR-4689 Is a Novel Treatment Against Mutant KRAS Colorectal Cancer
KRAS mutations are a major cause of drug resistance to molecular-targeted therapies. Aberrant epidermal growth factor receptor (EGFR) signaling may cause dysregulation of microRNA (miRNA) and gene regulatory networks, which leads to cancer initiation and progression. To address the functional releva...
Saved in:
Main Authors: | Masayuki Hiraki (Author), Junichi Nishimura (Author), Hidekazu Takahashi (Author), Xin Wu (Author), Yusuke Takahashi (Author), Masaaki Miyo (Author), Naohiro Nishida (Author), Mamoru Uemura (Author), Taishi Hata (Author), Ichiro Takemasa (Author), Tsunekazu Mizushima (Author), Jae-Won Soh (Author), Yuichiro Doki (Author), Masaki Mori (Author), Hirofumi Yamamoto (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2015-01-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
In silico analysis of wild-type and mutant KRAS
by: Frengki Frengki, et al.
Published: (2019) -
Super Carbonate Apatite-miR-497a-5p Complex Is a Promising Therapeutic Option against Inflammatory Bowel Disease
by: Naoto Tsujimura, et al.
Published: (2023) -
Targeting KRAS in Solid Tumors: Current Challenges and Future Opportunities of Novel KRAS Inhibitors
by: Alice Indini, et al.
Published: (2021) -
Kras: trajnostni razvoj kraške pokrajine
Published: (2008) -
Targeting the untargetable KRAS in cancer therapy
by: Pingyu Liu, et al.
Published: (2019)